Skip to main content

Table 3 Parameters during the follow-up in the ABC-reducing therapy group (n = 65). Dual therapy (DT) Alanine transaminase (ALT) Aspartate transaminase (AST) High-density lipoprotein (HDL) Low-density lipoprotein (HDL) Creatinine clearance (CCr) platelet-to-lymphocyte ratio (PLR) neutrophil-to-lymphocyte ratio (NLR)

From: Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: a multicenter retrospective cohort study from 2007 to 2015

Parameters 12 months
before
Mean (SD)
6 months before
Mean (SD)
Swicht to DT
Mean (SD)
6 months
after switch
Mean (SD)
12 months
after switch
Mean (SD)
From 12 months
before to switcha
Coef. (CI 95%)
p-value From switch to 12 months aftera
Coef. (CI 95%)
p-value
CD4 cell count, cell/mm3 629.9 (327.7) 656.6 (328) 678.1 (342.2) 677.4 (309.6) 658.9 (265.4) 1.3 (−2.3,4.9) 0.481 1.6 (−2.4,5.5) 0.435
CD8 cell count, cell/mm3 1023.5 (473.3) 1069.7 (664) 982.6 (461) 992.6 (526.1) 970.7 (446.6) −2.5 (− 10.5,5.5) 0.541 − 1.3 (− 7.3,4.6) 0.658
ALT (U/l) 40.1 (41.6) 43.5 (64.2) 44.5 (47.7) 45.9 (55.9) 36.7 (34.8) 0.4 (−0.9,1.6) 0.580 −0.2 (− 1.0,0.5) 0.536
AST (U/l) 30.2 (28.8) 31.2 (42) 29.6 (30) 32.7 (32.4) 30.1 (21.4) 0.1 (−0.8,0.9) 0.860 −0.1 (− 0.6,0.4) 0.761
Total Cholesterol (mg/dl) 218.5 (44.3) 220.8 (51.1) 227.2 (48.8) 218.4 (54.6) 215.5 (39.2) 0.6 (−0.3,1.5) 0.218 −1.6 (−2.6–0.6) 0.003
HDL Cholesterol (mg/dl) 47.2 (17.4) 53.5 (19.6) 49.8 (14.1) 53.9 (19.5) 52.8 (19.7) 0.1 (−0.2,0.4) 0.604 0.2 (−0.1,0.4) 0.168
LDL Cholesterol (mg/dl) 141.1 (38.3) 133.4 (35.5) 145.6 (42.4) 138.4 (30.9) 139.1 (27) 0.2 (−0.9,1.3) 0.742 −0.7 (1.7,0.2) 0.132
Triglycerides (mg/dl) 163.8 (92.2) 180.8 (110.9) 202.8 (115.5) 194.2 (234.4) 172.5 (161.1) 2.4 (0.3,4.6) 0.027 −3.8 (−8.4,0.9) 0.112
CCr (ml/min) 94.5 (31.5) 97 (35.8) 92.2 (26.8) 91.6 (28.5) 92.3 (30.9) 0.0 (−0.4,0.3) 0.852 −0.4 (− 0.8–0.1) 0.041
Lymphocyte, 103 /μL 2201 (662) 2197 (838) 2191 (663) 2256 (686) 2219 (655) 0.2 (−13.7,14.2) 0.972 6.5 (− 7.8,20.8) 0.373
Neutrophils, 103 /μL 3227 (1354) 3462 (1643) 3851 (3336) 3528 (1497) 6059 (10610) 40.7 (−32.7114.0) 0.277 153.3 (−82.1388.7) 0.202
Platelets, 103 /μL 216,173 (63378) 213,125 (68580) 211,927 (59231) 198,250 (60544) 217,611 (59716) −665.6 (− 1486.0, 154.7) 0.112 98.2 (− 781.3977.8) 0.827
NLR 1.5 (0.6) 1.7 (0.9) 1.8 (1.3) 1.7 (0.6) 1.7 (0.7) 0.2 (−0.2,0.5) 0.367 0.0 (−0.02,0.03) 0.840
PLR 106.9 (46.1) 108.5 (47.7) 104 (36.6) 92.5 (31.2) 107.5 (42.4) −0.4 (−1.3,0.5) 0.378 −0.2 (− 1.1,0.7) 0.645
CD4/CD8 0.73 (0.42) 0.76 (0.43) 0.82 (0.47) 0.81 (0.42) 0.79 (0.38) 0.005 (0.002,0.008) 0.003 0.002 (−0.001,0.006) 0.155
  1. In the analysis we performed random effects mixed models in order to evaluate the role of time (in months) on the changes in biochemical parameters
  2. aResults remained unchanged when sensitivity analysis by multiple imputation for missing data was performed